Evidence map›Paper›PMID 25576627›Full record

ArticleAmerican journal of physiology. Heart and circulatory physiology2015

Ca²⁺ entry via Trpm2 is essential for cardiac myocyte bioenergetics maintenance.

Nicholas E Hoffman, Barbara A Miller, JuFang Wang, John W Elrod, Sudasan Rajan, Erhe Gao, Jianliang Song, Xue-Qian Zhang, Iwona Hirschler-Laszkiewicz, Santhanam Shanmughapriya and 4 more

Abstract read
In one paragraph

Article in American journal of physiology. Heart and circulatory physiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Calcium and Heart Failure: How Did We Get Here and Where Are We Going?International journal of molecular sciences · 2021
    Review
  16. Article
  17. Frontiers in genetics · 2021
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nicholas E HoffmanCenter of Translational Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania; Department of Biochemistry, Temple University School of Medicine, Philadelphia, Pennsylvania; and.
Barbara A MillerDepartment of Pediatrics, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
JuFang WangCenter of Translational Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania;
John W ElrodCenter of Translational Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania;
Sudasan RajanCenter of Translational Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania; Department of Biochemistry, Temple University School of Medicine, Philadelphia, Pennsylvania; and.
Erhe GaoCenter of Translational Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania;
Jianliang SongCenter of Translational Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania;
Xue-Qian ZhangCenter of Translational Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania;
Iwona Hirschler-LaszkiewiczDepartment of Pediatrics, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
Santhanam ShanmughapriyaCenter of Translational Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania; Department of Biochemistry, Temple University School of Medicine, Philadelphia, Pennsylvania; and.
Walter J KochCenter of Translational Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania;
Arthur M FeldmanCenter of Translational Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania;
Muniswamy MadeshCenter of Translational Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania; Department of Biochemistry, Temple University School of Medicine, Philadelphia, Pennsylvania; and.
Joseph Y CheungCenter of Translational Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania; Division of Nephrology, Temple University School of Medicine, Philadelphia, Pennsylvania; Joseph.cheung@tuhs.temple.edu.

Funding

Regulation of Beta-Adrenergic Receptor Signaling by S-NitrosylationP01HL075443 · NHLBI · DUKE UNIVERSITY · PI STAMLER, JONATHAN S. · 2004 to 2019
$26.1M
Targeted Cancer Therapeutics and Heart Failure: Mechanisms and Post-injury RepairP01HL091799 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI HOUSER, STEVEN R · 2008 to 2018
$23.1M
Coordination of Pathophysiologic Endothelial Cell Signaling by ROSR01HL086699 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI MUNISWAMY, MADESH · 2008 to 2018
$4.3M
Targeting GRK2 in the HeartR01HL061690 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI KOCH, WALTER J. · 1998 to 2022
$4.2M
Involvement of BAG3 in HIV-1 induced cardiomyopathyR01HL123093 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI CHEUNG, JOSEPH Y, FELDMAN, ARTHUR M · 2014 to 2018
$3.7M
EXERCISE TRAINING IN POSTINFARCT HEARTR01HL058672 · NHLBI · WEIS CENTER FOR RESEARCH-GEISINGER CLINC · PI CHEUNG, JOSEPH Y · 1998 to 2012
$3.6M
GRK and b-Arrestin Signaling in Cardiac RegenerationR01HL085503 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI KOCH, WALTER J. · 2007 to 2015
$3.0M
Phospholemman and Cardiac ContractilityR01HL074854 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI CHEUNG, JOSEPH Y · 2005 to 2014
$2.8M
Gene Transfer and Myocardial FunctionR01HL056205 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI KOCH, WALTER J. · 1998 to 2008
$2.6M
SIGNAL TRANSDUCTION MECHANISMS OF ERYTHROPOIETINR01DK046778 · NIDDK · WEIS CENTER FOR RESEARCH-GEISINGER CLINC · PI MILLER, BARBARA A. · 1994 to 2011
$2.6M
Mechanisms of mitochondrial calcium exchange in heart failureR01HL123966 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI ELROD, JOHN WILLIAM · 2014 to 2018
$2.3M
NHLBI NIH HHS P01 HL091799NHLBI NIH HHS P01-HL-75443NHLBI NIH HHS P01-HL-91799NHLBI NIH HHS P01-HL91799NHLBI NIH HHS R01-HL123093NHLBI NIH HHS R01 HL123966NHLBI NIH HHS R01-HL56205NHLBI NIH HHS R01-HL58672NHLBI NIH HHS R01-HL61690NHLBI NIH HHS R01-HL74854NHLBI NIH HHS R01-HL85503NHLBI NIH HHS R01-HL86699NIDDK NIH HHS R01-DK46778
6 · The paper itself

Abstract

Ubiquitously expressed Trpm2 channel limits oxidative stress and preserves mitochondrial function. We first demonstrated that intracellular Ca(2+) concentration increase after Trpm2 activation was due to direct Ca(2+) influx and not indirectly via reverse Na(+)/Ca(2+) exchange. To elucidate whether Ca(2+) entry via Trpm2 is required to maintain cellular bioenergetics, we injected adenovirus expressing green fluorescent protein (GFP), wild-type (WT) Trpm2, and loss-of-function (E960D) Trpm2 mutant into left ventricles of global Trpm2 knockout (gKO) or WT hearts. Five days post-injection, gKO-GFP heart slices had higher reactive oxygen species (ROS) levels but lower oxygen consumption rate (OCR) than WT-GFP heart slices. Trpm2 but not E960D decreased ROS and restored OCR in gKO hearts back to normal levels. In gKO myocytes expressing Trpm2 or its mutants, Trpm2 but not E960D reduced the elevated mitochondrial superoxide (O2(.-)) levels in gKO myocytes. After hypoxia-reoxygenation (H/R), Trpm2 but not E906D or P1018L (inactivates Trpm2 current) lowered O2(.-) levels in gKO myocytes and only in the presence of extracellular Ca(2+), indicating sustained Ca(2+) entry is necessary for Trpm2-mediated preservation of mitochondrial function. After ischemic-reperfusion (I/R), cardiac-specific Trpm2 KO hearts exhibited lower maximal first time derivative of LV pressure rise (+dP/dt) than WT hearts in vivo. After doxorubicin treatment, Trpm2 KO mice had worse survival and lower +dP/dt. We conclude 1) cardiac Trpm2-mediated Ca(2+) influx is necessary to maintain mitochondrial function and protect against H/R injury; 2) Ca(2+) influx via cardiac Trpm2 confers protection against H/R and I/R injury by reducing mitochondrial oxidants; and 3) Trpm2 confers protection in doxorubicin cardiomyopathy.

Indexed as

Calcium SignalingEnergy MetabolismAction PotentialsAnimalsCalciumCardiomyopathiesDisease Models, AnimalDoxorubicinHEK293 CellsHumansMice, Inbred C57BLMice, KnockoutMitochondria, HeartMutationMyocardial ContractionMyocardial Reperfusion InjuryCalciumDoxorubicinReactive Oxygen SpeciesTRPM2 protein, mouseTRPM Cation Channelscardiac Trpm2 currentsdoxorubicin cardiomyopathyhypoxia-reoxygenationischemic cardiomyopathymitochondrial superoxidevoltage-independent Ca2+ channels

Identifiers

PMID25576627
PMCPMC4360055

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.